Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Dave4444on Dec 13, 2010 7:22pm
467 Views
Post# 17840789

KingWhatsi - you are way wrong on the TSFA sale

KingWhatsi - you are way wrong on the TSFA sale
You must be Canadian to have a TSFA, as such Canadian Income tax rules apply.  Ever hear of the "superficial loss rules"  if not you will.  If you sell or transfer losing shares into a TSFA you will lose the use of the capital loss forever.

Superficial loss rules kick in when you sell and then repurchase the shares within 30 days.   When you get the shares back within 30 days, you cannot use the loss, instead the loss reduces your cost for tax purposes of the new shares you acquired.  Problem with a TSFA is that since there are no gains or losses in the TSFA account, a reduction in the cost of the shares for tax purposes is useless and so the ability to reduce tax using the loss is gone forever.  What Jocotoco stated on the other hand, namely delaying sales until after the year-end so as to defer the tax payable on gains for a year, makes perfect sense and works just fine.  Only risk is you may have a gain in December but then see the stock price drop before you can sell in January.  I personally just take my profits when the markets offer them and then pay the tax.
Bullboard Posts